Colchicine

Overview

Colchicine (Colcrys®) is a unique anti-inflammatory drug occasionally used in veterinary medicine, primarily in dogs, for management of certain fibrotic or amyloid-associated conditions. It has been used particularly in Shar-Pei dogs with familial fever syndromes and in some cases of hepatic fibrosis or renal amyloidosis.

The drug has relatively limited clinical experience in veterinary patients, and its safety and efficacy have not been well established. Evidence supporting antifibrotic benefits in dogs is mostly anecdotal, and currently there is no clear evidence supporting its effectiveness for antifibrotic therapy in cats. Because adverse effects may occur relatively frequently, careful patient selection and monitoring are essential.

Mechanism of Action (MOA): Colchicine interferes with cell division by disrupting microtubule formation during metaphase, preventing normal mitotic spindle development. Its antifibrotic activity is believed to involve stimulation of collagenase activity and inhibition of collagen deposition. In addition, colchicine appears to suppress hepatic production of serum amyloid A (SAA), which may help reduce amyloid deposition in susceptible animals.

Indications

Colchicine is occasionally used in dogs as a specialized anti-inflammatory and antifibrotic agent. Its veterinary use remains limited, and evidence supporting its clinical effectiveness is largely anecdotal. In cats, there is currently no clear evidence supporting therapeutic benefit.

• Management of hepatic fibrosis and cirrhosis (dogs): Colchicine may be used as part of a medical management protocol for chronic liver diseases associated with fibrosis. The drug is believed to reduce collagen deposition through stimulation of collagenase activity, although evidence of clinical benefit remains limited.
• Renal amyloidosis (dogs): Occasionally used in dogs predisposed to amyloid deposition, particularly Shar-Pei dogs. Colchicine may reduce production of serum amyloid A and potentially slow amyloid accumulation in tissues.
• Shar-Pei fever–associated amyloidosis (dogs): Colchicine has been used in some Shar-Pei dogs with recurrent fever syndromes to help reduce amyloid deposition and associated complications.
• Post–endotracheal stent fibrosis (dogs): Reported in limited cases to reduce granulation tissue formation after tracheal or endotracheal stent placement, although supporting evidence is minimal.

Dosage (Reference)

Dog

In dogs, colchicine is administered orally. Treatment usually begins with a very low dose to reduce the risk of gastrointestinal side effects such as vomiting or diarrhea. If the medication is well tolerated, the dose may be increased slowly every few days.

Cat

Colchicine is not recommended for use in cats. There is currently no established safe or effective dosing information for this species, and clinical efficacy has not been demonstrated.

Warnings & Precautions

Colchicine has limited clinical experience in veterinary medicine and should be used cautiously in dogs. The drug has a relatively narrow safety margin and may cause significant adverse effects, particularly in animals with underlying systemic disease or when combined with interacting medications.

• Limited veterinary evidence: The safety and clinical effectiveness of colchicine have not been well established in animals. Its use in dogs is considered somewhat controversial and should be reserved for carefully selected cases.
• Gastrointestinal or cardiac disease: Colchicine is contraindicated in patients with serious gastrointestinal dysfunction or significant cardiac disease due to increased risk of complications.
• Renal or hepatic disease: Use cautiously in dogs with kidney or liver impairment. Dose reduction may be necessary, and severe renal or hepatic disease may increase the risk of toxicity.
• Geriatric or debilitated patients: Older or weakened animals may be more sensitive to the drug and should receive lower doses with careful monitoring.
• Concurrent medications: Dogs with severe renal or hepatic disease receiving drugs that inhibit CYP3A or P-glycoprotein may have a significantly increased risk of colchicine toxicity.
• Hazardous drug handling: Colchicine is classified by the National Institute for Occupational Safety and Health (NIOSH) as a hazardous drug. Appropriate precautions, including personal protective equipment, should be used when handling the medication.
• Pregnancy: Colchicine is considered teratogenic based on laboratory animal studies and should only be used during pregnancy if the potential benefits outweigh the risks.
• Reproductive effects: The drug may reduce spermatogenesis and could potentially affect fertility with prolonged use.
• Nursing animals: Colchicine can enter maternal milk; use cautiously in lactating animals when the expected benefit justifies the potential risk to offspring.

Drug Interactions

Colchicine has several clinically important drug interactions, mainly related to increased drug concentration, enhanced toxicity, or additive adverse effects. Careful monitoring and dose adjustment may be required when colchicine is used with the following medications.

• Azole antifungals (e.g., itraconazole, ketoconazole): May significantly increase colchicine plasma concentrations and the risk of toxicity due to inhibition of drug metabolism.
• Macrolide antibiotics (e.g., clarithromycin, erythromycin): Can increase colchicine levels and toxicity risk by interfering with drug metabolism pathways.
• Calcium channel blockers (e.g., diltiazem, verapamil): May increase colchicine concentrations and toxicity risk; caution is advised when these drugs are used together.
• Cyclosporine: Concurrent use may increase the risk of nephrotoxicity and bone marrow suppression.
• Amphotericin B: May increase the risk of kidney toxicity when used together with colchicine.
• Chloramphenicol: May cause additive bone marrow suppression or gastrointestinal adverse effects.
• Digoxin: Concurrent administration may increase the risk of muscle toxicity such as rhabdomyolysis.
• Fenofibrate or Gemfibrozil: May increase the risk of muscle injury or rhabdomyolysis when used with colchicine.
• Myelosuppressive drugs (e.g., antineoplastics, azathioprine): May cause additive bone marrow suppression when combined with colchicine.
• P-glycoprotein inhibitors (e.g., amiodarone, doxorubicin, spironolactone): May increase colchicine concentrations and raise the risk of toxicity.

Side Effects & Overdose

Side Effects

Experience with colchicine in veterinary patients is limited, but adverse effects have been reported in dogs, particularly at higher doses. Most side effects involve the gastrointestinal system, although more serious systemic effects can occur with prolonged use or excessive dosing.

• Gastrointestinal distress: Vomiting, diarrhea, nausea, and abdominal discomfort are the most commonly reported adverse effects in dogs.
• Myelosuppression: Bone marrow suppression, including neutropenia, may occur with prolonged therapy.
• Renal toxicity: Kidney dysfunction has been reported in rare cases.
• Peripheral neuropathy: Neurologic signs related to nerve damage may develop rarely with long-term use.
• Reduced vitamin B12 absorption: Long-term administration may impair cobalamin absorption.

Overdose

Colchicine overdose can be very serious and potentially life-threatening even at relatively small amounts above the recommended dose. Gastrointestinal signs are usually the earliest indicators of toxicity.

• Early signs: Loss of appetite, vomiting, abdominal pain, or diarrhea, which may progress to bloody diarrhea or paralytic ileus.
• Systemic toxicity: Kidney failure, liver injury, bone marrow suppression (pancytopenia), paralysis, and severe weakness may develop.
• Cardiovascular complications: Shock and vascular collapse may occur in severe poisoning.
• No specific antidote: Treatment is primarily supportive.
• Decontamination: Gastrointestinal decontamination may be attempted when ingestion is recent.
• Activated charcoal: Repeated doses may help reduce systemic absorption because the drug undergoes enterohepatic recycling.
• Supportive care: Management may include IV fluids, intensive monitoring, and treatment based on clinical signs.

Key Notes

Practical clinical points to consider when using colchicine in dogs:

• Narrow safety margin: Even small increases above the recommended dose may lead to toxicity, so careful dose calculation and monitoring are essential.
• Gradual dose adjustment: Therapy is usually started at a low dose and increased slowly over several days to improve tolerance.
• Shar-Pei predisposition: The drug has been used mainly in Shar-Pei dogs because of their risk for amyloidosis associated with recurrent fever syndromes.
• Antifibrotic mechanism: The drug may help reduce tissue fibrosis by promoting collagen breakdown through increased collagenase activity.
• Anti-amyloid effect: Colchicine may reduce production of serum amyloid A (SAA), which can help limit amyloid deposition in susceptible animals.
• Limited clinical evidence: Most veterinary uses are based on limited studies or anecdotal reports rather than strong controlled clinical trials.